**1. Introduction**

106 Psoriasis

Younai, F.S. & Phelan, J.A. (1997).Oral mucositis with features of Psoriasis: report of a case and review of the literature, *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*,84:61-67. Young, O. ; Murphy, M. ; Fitzgibbon, J. & O'Sullivan, P. (2009). Koebner phenomenon of the

Zhu, J.F. ; Kaminski, M.J. ; Pulitzer, D.R. ; Hu, J. & Thomas, H.F. (1996). Psoriasis:

pathophysiology and oral manifestations, *Oral Dis*, 2(2): 135-44.

ear canal skin, *Auris Nasus Larynx*, 36(1): 82-4.

Psoriasis is a chronic inflammatory disease affecting about 3% of the worldwide population (Gottlieb A et al, 2007).

Recent findings have shown that the previous concept " psoriasis as a disease of healthy people" must be revisited into psoriasis as a complex entity with multisistemic involvement.

Although the overall mortality attributed to psoriasis is about 0.64 deaths per 100 000 psoriatic patients annually in the USA, erythrodermic and generalized pustular soriasis, are associated with a greater risk of mortality and morbidity (Boyd AS et al, 1989; Prystowsky JH et al, 1995).

Psoriasis can be associated with other disease, such as metabolic syndrome, which may have a major impact on quality of life, morbidity and mortality.

The aim of this chapter is to focus on two newly emergent comorbidities in psoriatic patients, the cardiovascular disease (CVD) and the metabolic syndrome (MetS).
